Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Tang, GQ; Tang, YL; Dhamnaskar, K; Hoarty, MD; Vyasamneni, R; Vadysirisack, DD; Ma, Z; Zhu, NQ; Wang, JG; Bu, C; Cong, B; Palmer, E; Duda, PW; Sayegh, C; Ricardo, A

Tang, GQ (通讯作者)，UCB Pharm, Cambridge, MA USA.

FRONTIERS IN IMMUNOLOGY, 2023; 14 ():

Abstract

Introduction: The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of vario......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索